News

Sheetgo closes a round led by Caixa Capital Risc to finance the launch of its new platform [Article in Spanish]

The start-up, specialized in creating workflows from spreadsheets, will launch its new platform. It already reaches half a million users online and captures one million dollars to keep growing.

| Read more |

Minoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiary

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has appointed Mr. Didier Le Normand as Group CFO as well as General Manager of its recently opened Belgian subsidiary.

| Read more |

Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia.

FRAMES trial expected to initiate patient recruitment in upcoming weeks in Spain, Belgium and other European countries.
Two Key Opinion Leaders join Minoryx’s scientific advisory board.
In 2018 Minoryx closed a Series B funding round of €21.3M to expand the development of MIN-102 into new indications.

| Read more |

International investors boost Smartvel’s capital to increase its growth

Smartvel, a Spanish startup provider of destination content solutions for the tourism sector, has closed its second round of investment worth 1.05 million dollars, which will allow the tech company to continue to advance through the fast growing path that it has been maintaining thanks to its innovative technology based on Big Data, capable of collecting updated content from any destination in the world.

| Read more |

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, to jointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.

| Read more |